Jaleel Rajeeb, George John Titus, Thomas Ajith, Patel Lalji, John Anoop, Kurien Reuben Thomas, Simon Ebby George, Joseph A J, Dutta Amit Kumar, Chowdhury Sudipta Dhar
Department of Gastroenterology, Christian Medical College, Vellore, India.
Ann Gastroenterol. 2024 May-Jun;37(3):371-376. doi: 10.20524/aog.2024.0879. Epub 2024 Apr 22.
The role of rapid on-site evaluation (ROSE) for endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of pancreatic lesions is debatable. In this study, we aimed to compare the diagnostic yield of ROSE vs. non-ROSE in solid pancreatic lesions.
This retrospective single-center study included patients undergoing EUS-FNA of solid pancreatic lesions from 2019-2021. Patients with cystic lesions, those undergoing fine-needle core biopsy, those undergoing repeat procedures, and patients with non-diagnostic smears with less than 6-month follow up were excluded. The diagnostic yield, need for repeat procedures and number of passes required with and without ROSE were analyzed in these patients.
Of the 111 patients included, 56 underwent ROSE. The majority of lesions were malignant in both groups (79.6% ROSE vs. 75% non-ROSE). The diagnostic yield was 96.4% in the ROSE group and 94.5% in the non-ROSE group. Repeat samples were needed in 1 ROSE and 2 non-ROSE patients. The median number of passes made was significantly fewer in the ROSE group (3.5, interquartile range - 3,4) compared with the non-ROSE group (4, interquartile range - 3,5) P=0.01. However, the frequency of procedure-related complications was similar in both groups.
The utilization of ROSE during EUS-FNA of solid pancreatic lesions does not affect the diagnostic yield or the need for repeat samples, but reduces the number of passes needed for acquiring samples.
快速现场评估(ROSE)在胰腺病变内镜超声引导下细针穿刺抽吸术(EUS-FNA)中的作用存在争议。在本研究中,我们旨在比较ROSE与非ROSE在实性胰腺病变中的诊断率。
这项回顾性单中心研究纳入了2019年至2021年接受实性胰腺病变EUS-FNA的患者。排除有囊性病变的患者、接受细针芯活检的患者、接受重复操作的患者以及涂片诊断不明确且随访时间少于6个月的患者。分析这些患者在有ROSE和无ROSE情况下的诊断率、重复操作的必要性以及所需穿刺次数。
纳入的111例患者中,56例接受了ROSE。两组中大多数病变为恶性(ROSE组为79.6%,非ROSE组为75%)。ROSE组的诊断率为96.4%,非ROSE组为94.5%。1例ROSE患者和2例非ROSE患者需要重复采样。ROSE组的中位穿刺次数(3.5,四分位间距 - 3,4)明显少于非ROSE组(4,四分位间距 - 3,5),P = 0.01。然而,两组与操作相关的并发症发生率相似。
在实性胰腺病变的EUS-FNA过程中使用ROSE不影响诊断率或重复采样的必要性,但可减少获取样本所需的穿刺次数。